Clinical trials: Early Parkinson Disease (Early PD)
Parkinson Disease
AV133 Longitudinal Imaging Study in Patients With Early and Prdromal Parkinson's Disease
A total of 38 patients with early-stage Parkinson's disease and 38 patients with prodromal Parkinson's disease are planned to be enrolled in this study and examined for longitudinal changes in [18F]AV-133 through follow-up…
- Trial name
- NCT06456684
- Testing
- Fluoro[18F]promethazine
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Xuanwu Hospital, Beijing
Parkinson Disease
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
- Trial name
- NCT00321854
- Testing
- pramipexole
- Where
- 99 sites in United States, Austria and 8 more
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and…
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
- Trial name
- NCT05699460
- Testing
- This is an observational study.
- Where
- 11 sites in United States, Poland
- Volunteers
- 73 people
- Sponsor
- AskBio Inc
Early-stage Parkinson's Disease
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants…
- Trial name
- ORCHESTRA (NCT04658186)
- Testing
- UCB0599
- Where
- 115 sites in United States, Canada and 7 more
- Volunteers
- 496 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease (PD)
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease.
- Trial name
- NCT07725562
- Testing
- VG081821AC
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals, Ltd.
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Flexible-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-2 (NCT04223193)
- Testing
- Tavapadon
- Where
- 53 sites in United States, Australia and 11 more
- Volunteers
- 304 people
- Sponsor
- AbbVie
Parkinson Disease
Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)
Engage-PD is a single cohort evaluation of implementation of a telehealth-delivered physical activity coaching program for people with early-mid stage Parkinson's disease.
- Trial name
- Engage-PD (NCT04922190)
- Testing
- Physical Activity Coaching
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Teachers College, Columbia University
Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD)
Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)
The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population.
- Conditions
- Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD), Healthy Participants
- Trial name
- SAPHIR (NCT07083089)
- Testing
- Thorough Hearing assessment
- Where
- 4 sites in France
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Cilcare SAS
Parkinson Disease
Fixed-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
- Trial name
- TEMPO-1 (NCT04201093)
- Testing
- Tavapadon
- Where
- 77 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- AbbVie
Parkinson Disease
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo. Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and…
- Trial name
- NCT00402233
- Testing
- Pramipexole
- Where
- 39 sites in United States
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease (PD), Sarcopenia
Effectiveness of Resistance Exercises Added to Aerobic and Balance Exercises in Parkinson's Disease
The purpose of this study is to evaluate the effects of resistive exercises added to aerobic and balance exercises on quality of life, activities of daily living, cognitive functions, and sarcopenia parameters in patients…
- Trial name
- NCT07629063
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Parkinson's Disease (PD)
Parkinson's Research In Metagenomic Early Stage Biomarkers
This 2x2 factorial, randomized, controlled pilot study aims to identify a specific microbiota pattern, which could constitute a biomarker of Parkinson's disease, and to evaluate whether specific pathotypes can be associated with…
- Trial name
- PRIME_2025 (NCT07097103)
- Testing
- Mediterranean Diet Intervention, Intensive Physical Activity Intervention, Control
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS San Raffaele Roma
Parkinson's Disease
Study of IRX4204 for Treatment of Early Parkinson's Disease
This is a single site, open-label study designed to examine dopamine transporter density using [123I]β-CIT SPECT imaging before and following treatment with IRX4204 for a 30-day period in early Parkinson's disease patients.
- Trial name
- NCT02438215
- Testing
- IRX4204
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Io Therapeutics
Early Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
- Trial name
- NCT00332917
- Testing
- Pardoprunox
- Where
- 130 sites in United States, Argentina and 19 more
- Volunteers
- 224 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson Disease, Idiopathic
Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients
This study is a randomized, double-blind, controlled trial exploring the effects of long-term taVNS intervention in patients with early-stage Parkinson's disease.
- Trial name
- NLTVNSPD (NCT06665113)
- Testing
- taVNS real stimulation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Kezhong Zhang
Parkinson, Parkinson Disease
GRoningen Early-PD Ambroxol Treatment
The most common genetic risk factor for Parkinson's Disease is a heterozygous mutation of the GBA1 gene, encoding the lysosomal enzyme glucocerebrosidase (GCase).
- Trial name
- GREAT (NCT05830396)
- Testing
- Ambroxol Hydrochloride
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Parkinson&Amp;#39;s Disease
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
The purpose of this study is to determine if hydroxychloroquine is safe to take and whether there is potential for it to slow the progression of PD symptoms.
- Trial name
- NCT06816810
- Testing
- Hydroxychloroquine (HCQ)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Ottawa Hospital Research Institute
Parkinson Disease
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
- Trial name
- NCT04571164
- Testing
- LY03003(Rotigotine,extended-release microspheres)
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Luye Pharma Group Ltd.